Results 171 to 180 of about 218,137 (295)

CD4+ Tregs Drive Post‐Ischemic Sprouting Angiogenesis via Endothelial YY1/MAML1 Reactivation

Advanced Science, EarlyView.
ABSTRACT Microvascular complications of diabetes are chronic diseases of small vessels. We previously found that CD4+ regulatory T‐cells (Tregs) are markedly reduced in type 2 diabetes (T2D) after ischemic injury in both mice and humans, and that Treg deficiency in immunodeficient mice impairs vascular regeneration.
Hang Qu, Cheng Kiu Ho, Jitao Liu, Lei Cui, Yangfeng Hou, Cai Liang, Wenchu Ye, Randolph H. L. Wong, Shohei Hori, Bin Zhou, Kathy O. Lui   +10 more
wiley   +1 more source

644 Ocular adverse events associated with programmed death-1 and programmed death ligand-1 immunotherapy

Journal for ImmunoTherapy of Cancer, 2020
James Murray, Howard Streicher, Elad Sharon, Helen Chen, LeAnne Young, Shanda Finnigan, H Nida Sen   +6 more
doaj   +1 more source

Bibliometric analysis of programmed death ligand-1 positron emission tomography probe research: development, landscape, and technological evolution. [PDF]

Nucl Med Commun
Lin K, Li M, Wang Y, Chen Z, Miao W.
europepmc   +1 more source

Hijacking the Host Clock: A Nematode Effector Antagonizes Soybean Circadian Defense and Translation Control

Advanced Science, EarlyView.
Soybean employs its circadian clock, governed by GmCCA1, to rhythmically defend against soybean cyst nematodes. The pathogen retaliates by secreting the effector Hg4E02, which hijacks the clock to suppress defense and co‐opt the host's translation machinery for nutrient acquisition.
Xingwei Wang, Yufeng Xu, Yanfei Hu, Lijun Cao, Ru Jiang, Changtian Chen, Rick Masonbrink, Thomas Maier, Yuchen Tu, Yabo Shi, Enhui Liu, Lingan Kong, Chan Guo, Wei Zhao, Peng Shi, Wenzhen Du, Andrew Severin, Thomas Baum, Deliang Peng, Huan Peng, Mian Zhou, Wei Wang   +21 more
wiley   +1 more source

Choice of fixative affects programmed death-ligand 1 expression in cell blocks from pleural effusions with metastatic pulmonary adenocarcinoma. [PDF]

Cancer Cytopathol
Mansour MSI, Pettersson L, Pedersen R, Mager U, Hejny K, Kronqvist F, Aronsson A, Seidal T, Akyürek LM, Kholová I.   +9 more
europepmc   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Programmed Cell Death 1 Ligand 1 [PDF]

, 2020
openaire   +1 more source

Programmed Death-Ligand 1 Expression Predicts Poor Prognosis in Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy. [PDF]

Thorac Cancer
Park J, Yea JW, Park JW, Jo YY, Oh SA, Park J.   +5 more
europepmc   +1 more source

Tumor‐Derived LAMB3 Drives Immunosuppressive LRRC15+ Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development

Advanced Science, EarlyView.
A single‐cell atlas of pancreatic ductal adenocarcinoma development reveals progressive ductal‐fibroblast‐immune crosstalk. Tumor‐derived LAMB3 drives the formation of immunosuppressive LRRC15+ fibroblasts through the ITGB1/FAK/MAPK/FOSL2 signaling. Glycolytic reprogramming upregulates LAMB3 and correlates with LRRC15+ fibroblast enrichment.
Xuqing Shi, Hangqi Liu, Jianru Sun, Xiaoding Liu, Xinping Jv, Longyun Chen, Yuhan Zhang, Hui Zhang, Xudong Xing, Ruiyu Li, Xinyi Ke, Jun Wang, Xianglin Yin, Bohan Liu, Qixian Liu, Yuan Wang, Junliang Lu, Shiyi Liu, Junyi Pang, Yumeng Cai, Menghua Dai, Fan Bai, Huanwen Wu, Zhiyong Liang   +23 more
wiley   +1 more source

Programmed death-ligand 1 upregulation is associated with poor prognosis in patients with epithelial ovarian cancer. [PDF]

J Chin Med Assoc
Liu CH, Chao WT, Yang ST, Lin CH, Wen KC, Wang PH.   +5 more
europepmc   +1 more source